

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number	8
	08/888.350	1623		
Notice of References Cited	APPLICANT(S)  Or et al.			

### U. S. Patent Documents


*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	5 5 2 7 7 8 0	06/08/96	Agouridas et al. (I)	514	029.000	
*	B	5 5 6 1 1 1 8	10/01/96	Agouridas et al. (II)	514	029.000	
*	C	5 3 5 0 8 3 9	09/27/94	Asaka et al.	536	007.400	
*	D*	5 4 4 4 0 5 1	08/22/95	Agouridas et al. (III)	514	029.000	

\* Supplied by Applicant with incorrect PTO-1449 citation.

### Foreign Patent Documents

		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	0 5 6 5 3 6 4	06/07/95	Europe(EPO)	Roussel-UCLAF	-----	-----		
*	M	9 3 2 1 2 0 0	10/28/93	WO(PCT)	Taisho Pharma.	-----	-----		
*	N	0 6 8 0 9 6 7	11/08/95	Europe(EPO)	Roussel-UCLAF	-----	-----		
*	O	0 6 7 6 4 0 9	10/11/95	Europe(EPO)	Roussel-UCLAF	-----	-----		
*	P	2 6 9 7 5 2 4	05/06/94	France	Roussel-UCLAF	-----	-----		
*	Q	9 3 2 1 1 9 9	10/28/93	WO(PCT)	Taisho Pharma.	-----	-----		
*	LA	0 4 8 7 4 1 1	05/27/92	Europe(EPO)	Roussel-UCLAF	-----	-----		
*	MA	9 3 1 3 1 1 6	07/08/93	WO(PCT)	Taisho Pharma.	-----	-----		
*	NA	9 3 1 3 6 6 3	07/22/93	WO(PCT)	Abbott Labs.	-----	-----		
*	OA*	0 5 9 6 8 0 2	05/11/94	Europe(EPO)	Roussel-UCLAF	-----	-----		
*	PA*	9 7 1 0 2 5 1	03/20/97	WO(PCT)	Roussel-UCLAF	-----	-----		
*	QA*	9 2 0 9 6 1 4	06/11/92	WO(PCT)	Taisho Pharma.	-----	-----		

\* Supplied by Applicant.

EXAMINER L. Eric Crane 	DATE 03/23/98	page 1 of 2 Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Copy for ☒ FILE ☐ APPLICANT


Form PTO-892 U.S. Department of Commerce	Serial Number <b>08/888,350</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number	<b>8</b>
Notice of References Cited	APPLICANT(S)  Or et al.			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* R	Pestka et al. (I), "Effect of Erythromycin Analogues on Binding of [ <sup>14</sup> C]Erythromycin to <i>Escherichia coli</i> Ribosomes," <u>Antimicrobial Agents and Chemotherapy</u> , 6(4), 479-488 (October 1974).
* S	Pestka et al. (II), "Correlation of Effects of Erythromycin Analogues on Intact Bacteria and on [ <sup>14</sup> C]Erythromycin Binding to <i>Escherichia coli</i> Ribosomes," <u>Antimicrobial Agents and Chemotherapy</u> , 6(4), 488-491 (October 1974).
* T	Pestka et al. (III), "Inhibition of [ <sup>14</sup> C]Chloramphenicol Binding to <i>Escherichia coli</i> Ribosomes by Erythromycin Derivatives," <u>Antimicrobial Agents and Chemotherapy</u> , 6(1), 39-45 (July 1974).
* U	Pestka et al. (IV), "Induction of Erythromycin Resistance in <i>Staphylococcus aureus</i> by Erythromycin Derivatives," <u>Antimicrobial Agents and Chemotherapy</u> , 9(1), 128-130 (January 1976).
* V	LeMahieu et al., "Glycoside Cleavage Reactions on Erythromycin A. Preparation of Erythronolide A," <u>J. Medicinal Chem.</u> , 17(9), 953-956 (September 1974).

\* Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

‡ Supplied by Applicant.

EXAMINER L. Eric Crane 	DATE 03/23/98	page 2 of 2 Ⓢ: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Copy for ☒ FILE ☐ APPLICANT